Published in Infect Dis Clin North Am on March 01, 2007
Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis. Lancet Infect Dis (2008) 5.85
Effects through 24 months of an HIV/AIDS prevention intervention program based on protection motivation theory among preadolescents in the Bahamas. Pediatrics (2009) 1.53
The impact of antiretroviral therapy on HPV and cervical intraepithelial neoplasia: current evidence and directions for future research. Infect Agent Cancer (2010) 1.32
Novel bimodular DNA aptamers with guanosine quadruplexes inhibit phylogenetically diverse HIV-1 reverse transcriptases. Nucleic Acids Res (2008) 1.00
HIV and intestinal parasite co-infections among a Chinese population: an immunological profile. Infect Dis Poverty (2013) 0.96
Screening for HIV-associated dementia in South Africa: potentials and pitfalls of task-shifting. AIDS Patient Care STDS (2011) 0.88
Paediatric radiology seen from Africa. Part II: recognising research advantages in a developing country. Pediatr Radiol (2011) 0.86
Impact of childhood trauma on functionality and quality of life in HIV-infected women. Health Qual Life Outcomes (2011) 0.83
Factors Associated with Low Levels of HIV Testing among Men Who Have Sex with Men (MSM) in Brazil. PLoS One (2015) 0.83
CD4 count is associated with postoperative infection in patients with orthopaedic trauma who are HIV positive. Clin Orthop Relat Res (2011) 0.79
Antiretroviral Treatment and Sexual Risk Behavior in South Africa. AIDS Behav (2016) 0.77
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science (2010) 35.19
Towards an improved investment approach for an effective response to HIV/AIDS. Lancet (2011) 11.89
Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med (2010) 10.90
Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infect Dis (2002) 6.73
The potential impact of male circumcision on HIV in Sub-Saharan Africa. PLoS Med (2006) 6.53
Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS (2011) 6.26
Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS (2006) 5.31
Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med (2011) 5.31
Measurement of trends in childhood malaria mortality in Africa: an assessment of progress toward targets based on verbal autopsy. Lancet Infect Dis (2003) 4.10
Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection. N Engl J Med (2015) 3.64
Establishing a cohort at high risk of HIV infection in South Africa: challenges and experiences of the CAPRISA 002 acute infection study. PLoS One (2008) 3.40
Achieving the health Millennium Development Goals for South Africa: challenges and priorities. Lancet (2009) 3.35
AIDS among older children and adolescents in Southern Africa: projecting the time course and magnitude of the epidemic. AIDS (2009) 2.92
HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet (2006) 2.86
HIV infection, antiretroviral therapy, and CD4+ cell count distributions in African populations. J Infect Dis (2006) 2.82
Malaria attributable to the HIV-1 epidemic, sub-Saharan Africa. Emerg Infect Dis (2005) 2.80
The global impact of scaling up HIV/AIDS prevention programs in low- and middle-income countries. Science (2006) 2.76
Improving facility-based care for sick children in Uganda: training is not enough. Health Policy Plan (2005) 2.61
Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med (2012) 2.48
Symptomatic vaginal discharge is a poor predictor of sexually transmitted infections and genital tract inflammation in high-risk women in South Africa. J Infect Dis (2012) 2.42
Microbicides & their implications in HIV prevention. Indian J Med Res (2010) 2.36
GB virus type C coinfection in HIV-infected African mothers and their infants, KwaZulu Natal, South Africa. Clin Infect Dis (2004) 2.08
Pediatric mortality in Africa: plasmodium falciparum malaria as a cause or risk? Am J Trop Med Hyg (2004) 1.98
Global development. Family planning and the Millennium Development Goals. Science (2010) 1.78
Improving quality and efficiency of facility-based child health care through Integrated Management of Childhood Illness in Tanzania. Health Policy Plan (2005) 1.77
Innate immune activation enhances hiv acquisition in women, diminishing the effectiveness of tenofovir microbicide gel. J Infect Dis (2012) 1.73
Prevalence of HIV among truck drivers visiting sex workers in KwaZulu-Natal, South Africa. Sex Transm Dis (2002) 1.66
Estimating HIV incidence among adults in Kenya and Uganda: a systematic comparison of multiple methods. PLoS One (2011) 1.56
Effect of Integrated Management of Childhood Illness (IMCI) on health worker performance in Northeast-Brazil. Cad Saude Publica (2004) 1.52
The impact of incident and prevalent herpes simplex virus-2 infection on the incidence of HIV-1 infection among commercial sex workers in South Africa. J Acquir Immune Defic Syndr (2005) 1.51
Preventing HIV infection in women: a global health imperative. Clin Infect Dis (2010) 1.47
Changing patterns of knowledge, reported behaviour and sexually transmitted infections in a South African gold mining community. AIDS (2003) 1.42
Diabetes and other disorders of glycemia in a rural South African community: prevalence and associated risk factors. Diabetes Care (2008) 1.40
The relationship between obesity and complications after neonatal circumcision. J Urol (2011) 1.39
Epidemiological impact of tenofovir gel on the HIV epidemic in South Africa. J Acquir Immune Defic Syndr (2011) 1.31
The changing epidemiology of HIV in 2013. Curr Opin HIV AIDS (2013) 1.31
The distribution of new HIV infections by mode of exposure in Morocco. Sex Transm Infect (2013) 1.24
Utility of tuberculosis directly observed therapy programs as sites for access to and provision of antiretroviral therapy in resource-limited countries. Clin Infect Dis (2004) 1.18
Genital tract inflammation during early HIV-1 infection predicts higher plasma viral load set point in women. J Infect Dis (2012) 1.17
Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. Trials (2011) 1.15
Understanding the modes of transmission model of new HIV infection and its use in prevention planning. Bull World Health Organ (2012) 1.14
Contraceptive choices, pregnancy rates, and outcomes in a microbicide trial. Obstet Gynecol (2011) 1.13
Ratio of monocytes to lymphocytes in peripheral blood identifies adults at risk of incident tuberculosis among HIV-infected adults initiating antiretroviral therapy. J Infect Dis (2013) 1.12
Disclosure of microbicide gel use to sexual partners: influence on adherence in the CAPRISA 004 trial. AIDS Behav (2014) 1.09
Utilizing nucleic acid amplification to identify acute HIV infection. AIDS (2007) 1.07
Adherence in the CAPRISA 004 tenofovir gel microbicide trial. AIDS Behav (2014) 1.06
HIV prevalence among high school learners - opportunities for schools-based HIV testing programmes and sexual reproductive health services. BMC Public Health (2012) 1.04
Interventions to modify sexual risk behaviours for preventing HIV in homeless youth. Cochrane Database Syst Rev (2011) 0.98
Modelling the impact of antiretroviral therapy on the epidemic of HIV. Curr HIV Res (2011) 0.98
Preservation HIV-1-specific IFNγ+ CD4+ T-cell responses in breakthrough infections after exposure to tenofovir gel in the CAPRISA 004 microbicide trial. J Acquir Immune Defic Syndr (2012) 0.97
Natural killer cell function in women at high risk for HIV acquisition: insights from a microbicide trial. AIDS (2012) 0.96
When to start antiretroviral therapy during tuberculosis treatment? Curr Opin Infect Dis (2013) 0.94
Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 Trial. Antivir Ther (2012) 0.94
Topical microbicides--what's new? J Acquir Immune Defic Syndr (2013) 0.92
Antiretroviral therapy: challenges and options in South Africa. Lancet (2003) 0.91
Overview of microbicides for the prevention of human immunodeficiency virus. Best Pract Res Clin Obstet Gynaecol (2012) 0.90
Prevention of HIV in Adolescent Girls and Young Women: Key to an AIDS-Free Generation. J Acquir Immune Defic Syndr (2017) 0.89
Limited HIV-1 superinfection in seroconverters from the CAPRISA 004 Microbicide Trial. J Clin Microbiol (2013) 0.87
The preventive misconception: experiences from CAPRISA 004. AIDS Behav (2014) 0.86
The SAPIT trial provides essential evidence on risks and benefits of integrated and sequential treatment of HIV and tuberculosis. S Afr Med J (2010) 0.85
Experience in international clinical research: the HIV Prevention Trials Network. Clin Investig (Lond) (2011) 0.84
Trends in HIV Prevalence in Pregnant Women in Rural South Africa. J Acquir Immune Defic Syndr (2015) 0.84
Epidemiological Trends for HIV in Southern Africa: Implications for Reaching the Elimination Targets. Curr HIV/AIDS Rep (2015) 0.84
Neither microbial translocation nor TLR responsiveness are likely explanations for preexisting immune activation in women who subsequently acquired HIV in CAPRISA 004. J Acquir Immune Defic Syndr (2013) 0.83
A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection. Expert Opin Investig Drugs (2012) 0.82
The HIV epidemic in Southern Africa - Is an AIDS-free generation possible? Curr HIV/AIDS Rep (2014) 0.82
HIV-Associated Tuberculosis. Clin Dev Immunol (2010) 0.81
Vertical HIV transmission in South Africa: translating research into policy and practice. Lancet (2002) 0.79
Monitoring microbicide gel use with real-time notification of the container's opening events: results of the CAPRISA Wisebag study. AIDS Behav (2014) 0.79
Diverse approaches useful for microbicide trials. Nature (2007) 0.79
Implementing microbicides in low-income countries. Best Pract Res Clin Obstet Gynaecol (2012) 0.78
Microbicides for the prevention of sexually transmitted HIV infection. Expert Rev Anti Infect Ther (2013) 0.78
Integrated Management of Childhood Illness: efficiency of primary health in Northeast Brazil. Rev Saude Publica (2008) 0.78
Microbicides for prevention of HIV infection: clinical efficacy trials. Curr Top Microbiol Immunol (2014) 0.77
Metabolic Syndrome After HIV Acquisition in South African Women. J Acquir Immune Defic Syndr (2016) 0.77
Antibodies for HIV prevention in young women. Curr Opin HIV AIDS (2015) 0.77
HIV prevalence measurement in household surveys: is awareness of HIV status complicating the gold standard? AIDS (2013) 0.77
Anti-retrovirals for treatment and prevention--time for new paradigms in our response to the HIV/AIDS epidemic? Dev World Bioeth (2013) 0.77
Level of viral suppression and the cascade of HIV care in a South African semi-urban setting in 2012. AIDS (2016) 0.76
Representative sampling and analysis in HIV molecular epidemiology studies. AIDS (2008) 0.76
Early evolution of HLA-associated escape mutations in variable Gag proteins predicts CD4+ decline in HIV-1 subtype C infected women. AIDS (2016) 0.75
Genital-Systemic Chemokine Gradients and the Risk of HIV Acquisition in Women. J Acquir Immune Defic Syndr (2017) 0.75
Safety of coitally administered tenofovir 1% gel, a vaginal microbicide, in chronic hepatitis B virus carriers: results from the CAPRISA 004 trial. Antiviral Res (2013) 0.75
Prevention of HIV by male circumcision. BMJ (2007) 0.75
Tenofovir Gel to Prevent HSV-2 Infection. N Engl J Med (2015) 0.75
Brief Report: Selection of HIV-1 Variants With Higher Transmission Potential by 1% Tenofovir Gel Microbicide. J Acquir Immune Defic Syndr (2017) 0.75
Meeting the sexual and reproductive health needs of high-school students in South Africa: experiences from rural KwaZulu-Natal. S Afr Med J (2014) 0.75
The power of HIV/AIDS epidemiology. Curr Opin HIV AIDS (2009) 0.75
Serum glycan-binding IgG antibodies in HIV-1 infection and during the development of broadly neutralizing responses. AIDS (2017) 0.75
Genital - Systemic chemokine gradients and the risk of HIV acquisition in women. J Acquir Immune Defic Syndr (2016) 0.75